Therapyx Inc. News http://therapyxinc.com News and Events for Therapyx Inc. CGFeedMaker 1.0.17 on CMS Made Simple info@therapyxinc.com The National Institutes of Health awards a grant in the amount of $1,793,879 to TherapyXinc http://therapyxinc.com/news/11/65/The-National-Institutes-of-Health-awards-a-grant-in-the-amount-of-1-793-879-to-TherapyXinc TherapyX is pleased to announce a new SBIR Phase II award to continue development of GvaX12 ® , a completely novel prophylactic vaccine against genital tract infections including Gonorrhea and potentially chlamydia. Tue, 14 Mar 2017 16:23:32 -0400 http://therapyxinc.com/news/11/65/The-National-Institutes-of-Health-awards-a-grant-in-the-amount-of-1-793-879-to-TherapyXinc TherapyX, Inc is Awarded Phase I Funding http://therapyxinc.com/news/10/65/TherapyX-Inc-is-Awarded-Phase-I-Funding TherapyX, Inc is Awarded $295,000 in new SBIR Phase I Funding to test IL10NanoCap in inflammatory bowel disease. Thu, 03 Nov 2016 15:04:25 -0400 http://therapyxinc.com/news/10/65/TherapyX-Inc-is-Awarded-Phase-I-Funding THERAPYXINC ANNOUNCES RELOCATION OF ITS HEADQUARTERS TO LOUISVILLE, KENTUCKY. http://therapyxinc.com/news/9/65/THERAPYXINC-ANNOUNCES-RELOCATION-OF-ITS-HEADQUARTERS-TO-LOUISVILLE-KENTUCKY Louisville, KY – July 1 st 2015  – TherapyX inc is pleased to announce the relocation of his headquarters and main base of operations to Louisville Kentucky Wed, 12 Aug 2015 11:19:38 -0400 http://therapyxinc.com/news/9/65/THERAPYXINC-ANNOUNCES-RELOCATION-OF-ITS-HEADQUARTERS-TO-LOUISVILLE-KENTUCKY TherapyX, Inc. is Awarded Phase II SBIR funding http://therapyxinc.com/news/7/65/TherapyX-Inc-is-Awarded-Phase-II-SBIR-funding Therapyx, Inc. is awarded 1.49 million dollars to develop the immune-modulatory therapeutic … Thu, 12 Jun 2014 14:02:20 -0400 http://therapyxinc.com/news/7/65/TherapyX-Inc-is-Awarded-Phase-II-SBIR-funding TherapyX, Inc. is Awarded Phase I SBIR funding http://therapyxinc.com/news/4/65/TherapyX-Inc-is-Awarded-Phase-I-SBIR-funding Therapyx, Inc. is awarded $300,000 to develop the immune-modulatory therapeutic IL12NanoCap TM  for the treatment of genital tract infections. Fri, 01 Feb 2013 00:00:00 -0500 http://therapyxinc.com/news/4/65/TherapyX-Inc-is-Awarded-Phase-I-SBIR-funding TherapyX, Inc. Partners with Neumedicines http://therapyxinc.com/news/5/65/TherapyX-Inc-Partners-with-Neumedicines TherapyX, Inc. and Neumedicines Inc. sign a collaborative agreement to advance TherapyX’s anti-cancer drug IL12 NanoCap TM  through Phase I clinical trials. Mon, 23 Jul 2012 15:59:23 -0400 http://therapyxinc.com/news/5/65/TherapyX-Inc-Partners-with-Neumedicines